Paclitaxel poliglumex

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Paclitaxel poliglumex
Accession Number
DB13809
Type
Small Molecule
Groups
Experimental, Investigational
Description
Not Available
Synonyms
Not Available
External IDs
CT-2103
Categories
UNII
TQ64FZ98ZN
CAS number
263351-82-2
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Paclitaxel poliglumex.
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Paclitaxel poliglumex.
AldoxorubicinThe risk or severity of cardiotoxicity can be increased when Aldoxorubicin is combined with Paclitaxel poliglumex.
AmsacrineThe risk or severity of cardiotoxicity can be increased when Amsacrine is combined with Paclitaxel poliglumex.
AnastrozoleThe risk or severity of cardiotoxicity can be increased when Anastrozole is combined with Paclitaxel poliglumex.
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Paclitaxel poliglumex.
Arsenic trioxideThe risk or severity of cardiotoxicity can be increased when Arsenic trioxide is combined with Paclitaxel poliglumex.
BevacizumabThe risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Paclitaxel poliglumex.
BleomycinThe risk or severity of cardiotoxicity can be increased when Bleomycin is combined with Paclitaxel poliglumex.
BortezomibThe risk or severity of cardiotoxicity can be increased when Bortezomib is combined with Paclitaxel poliglumex.
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available
ATC Codes
L01CD03 — Paclitaxel poliglumex

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAdvanced Colorectal Cancer1
1CompletedTreatmentCancer, Breast / Metastatic Breast Cancer (MBC)1
1CompletedTreatmentFallopian Tube Carcinoma / Malignant Ovarian Mixed Epithelial Tumor / Ovarian Brenner Tumor / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Cystadenocarcinoma / Ovarian Serous Cystadenocarcinoma / Primary Peritoneal Carcinoma / Stage III Ovarian Cancer / Stage IV Ovarian Cancer / Undifferentiated Ovarian Carcinoma1
1, 2CompletedTreatmentCancer of the Ovary / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
1, 2RecruitingTreatmentSquamous Cell Carcinoma (SCC)1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentCancer, Breast / Metastatic Breast Cancer (MBC)1
2CompletedTreatmentPrimary Peritoneal Carcinoma / Recurrent Ovarian Carcinoma1
2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2TerminatedTreatmentProstate Cancer1
3Active Not RecruitingTreatmentFallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Endometrioid Adenocarcinoma / Fallopian Tube Mucinous Adenocarcinoma / Fallopian Tube Serous Adenocarcinoma / Fallopian Tube Transitional Cell Carcinoma / Malignant Ovarian Mixed Epithelial Tumor / Ovarian Brenner Tumor / Ovarian Clear Cell Adenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Adenocarcinoma / Ovarian Serous Adenocarcinoma / Ovarian Transitional Cell Carcinoma / Primary Peritoneal Serous Adenocarcinoma / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIA Primary Peritoneal Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Primary Peritoneal Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Primary Peritoneal Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer / Stage IV Primary Peritoneal Cancer / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
3TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3Unknown StatusTreatmentLung Cancers4

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on June 23, 2017 14:49 / Updated on November 02, 2018 07:46